Insmed, Inc. (NASDAQ:INSM) Stock Rated “Buy” by Sell-Side Analysts

Insmed, Inc. (NASDAQ:INSM) has been given a consensus rating of “Buy” by the twenty-five brokerages that are covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, twenty-two have given a buy recommendation and two have issued a strong buy recommendation on the company. The average 12-month target price among brokers that have issued a report on the stock in the last year is $201.87.

A number of analysts have commented on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Insmed in a research note on Friday, July 17th. HC Wainwright restated a “buy” rating on shares of Insmed in a research note on Monday, August 10th. Mizuho set a $192.00 target price on shares of Insmed in a report on Tuesday, June 16th. Royal Bank Of Canada cut their target price on shares of Insmed from $205.00 to $195.00 and set an “outperform” rating for the company in a research note on Friday, June 5th. Finally, UBS Group reiterated a “buy” rating and set a $172.00 price target on shares of Insmed in a report on Friday, August 7th.

Insmed Stock Down 1.7%

NASDAQ:INSM opened at $115.63 on Friday. The firm has a market capitalization of $25.25 billion, a price-to-earnings ratio of -28.13 and a beta of 0.82. Insmed has a twelve month low of $90.39 and a twelve month high of $212.75. The stock’s 50 day moving average price is $119.95 and its two-hundred day moving average price is $121.78. The company has a quick ratio of 3.40, a current ratio of 3.72 and a debt-to-equity ratio of 0.74.

Insmed (NASDAQ:INSM) last announced its quarterly earnings data on Thursday, August 6th. The biopharmaceutical company reported ($0.06) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.67) by $0.61. Insmed had a negative return on equity of 123.94% and a negative net margin of 76.94%.The company had revenue of $425.49 million for the quarter, compared to analysts’ expectations of $395.50 million. During the same quarter in the prior year, the business posted ($1.70) EPS. The business’s revenue was up 296.1% compared to the same quarter last year. Equities research analysts expect that Insmed will post -1.84 earnings per share for the current fiscal year.

Insider Buying and Selling at Insmed

In other news, CEO William Lewis sold 10,699 shares of Insmed stock in a transaction that occurred on Thursday, July 9th. The stock was sold at an average price of $117.40, for a total transaction of $1,256,062.60. Following the completion of the transaction, the chief executive officer directly owned 259,058 shares in the company, valued at approximately $30,413,409.20. The trade was a 3.97% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Roger Adsett sold 239,850 shares of the business’s stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $133.27, for a total value of $31,964,809.50. Following the transaction, the chief operating officer directly owned 98,744 shares in the company, valued at $13,159,612.88. The trade was a 70.84% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 275,549 shares of company stock worth $36,320,872 over the last 90 days. Company insiders own 2.10% of the company’s stock.

Hedge Funds Weigh In On Insmed

Several large investors have recently modified their holdings of INSM. Andra AP fonden lifted its stake in shares of Insmed by 55.9% during the 2nd quarter. Andra AP fonden now owns 121,570 shares of the biopharmaceutical company’s stock worth $12,962,000 after buying an additional 43,600 shares during the last quarter. WINTON GROUP Ltd acquired a new position in Insmed in the 2nd quarter valued at about $400,000. C WorldWide Group Holding A S raised its holdings in Insmed by 62.1% in the 2nd quarter. C WorldWide Group Holding A S now owns 261,110 shares of the biopharmaceutical company’s stock valued at $27,840,000 after acquiring an additional 100,000 shares during the period. NewEdge Advisors LLC raised its holdings in Insmed by 22.3% in the 2nd quarter. NewEdge Advisors LLC now owns 7,354 shares of the biopharmaceutical company’s stock valued at $784,000 after acquiring an additional 1,339 shares during the period. Finally, IFP Advisors Inc lifted its position in Insmed by 28.5% during the second quarter. IFP Advisors Inc now owns 2,945 shares of the biopharmaceutical company’s stock worth $314,000 after acquiring an additional 654 shares during the last quarter.

About Insmed

Insmed Incorporated is a global biopharmaceutical company focused on developing and commercializing therapies for patients with serious and rare diseases. The company’s research and development activities center on pulmonary and inflammatory conditions, with an emphasis on diseases that have limited treatment options.

Insmed’s principal commercial product is ARIKAYCE liposomal, an inhaled formulation of amikacin used with a combination antibacterial regimen to treat refractory Mycobacterium avium complex lung disease in certain adult patients.